Biopharma AI
By
Could Everest Medicines’ AI-Powered mRNA Platform Signal a Turning Point for Cancer and Autoimmune Therapies in Asia?
Key Highlights Reimagining Cancer Vaccines with AI-Optimized PersonalizationAt the 2025 Everest Medicines R&D Day, the company showcased EVM16,…
Shift Bioscience Unveils AI Framework to Improve Gene Target Discovery for Rejuvenation Therapies
Key Highlights Deeper DiveCambridge-based Shift Bioscience is rethinking how AI models are evaluated for rejuvenation research. Their study,…
Can Syntis Bio’s $38M Series A Transform Oral Biologics for Obesity and Rare Diseases?
Key Highlights Funding to Advance Novel Oral TherapiesBoston-based Syntis Bio announced the close of its $38 million financing…
Can Argon AI’s $5.5M Funding Transform Biopharma with an AI-Native Workspace to End Data Drudgery?
Key Takeaways Argon AI Secures Strategic Backing for AI-Native Biopharma WorkspaceArgon AI has raised $5.5 million in a…
Can Catalio Capital’s $400 Million AI-Driven Life Sciences Fund Ignite a New Era of Biomedical Innovation Despite a Slow VC Market?
Key Takeaways Resilience in a Cooling VC ClimateCatalio Capital Management has successfully closed its fourth Nexus Fund at…
Is Portal Biotech’s $35M Series A Set to Redefine Proteomics With the World’s First AI-Powered Full-Length Single-Molecule Protein Sequencer?
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
How Is XtalPi’s Expanded Collaboration With Pfizer Set to Transform AI-Driven Small Molecule Drug Discovery?
Key Takeaways Empowering Next-Gen AI Platforms for Predictive Drug DiscoveryXtalPi and Pfizer have extended their strategic partnership to…
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird Bioscience Signs $290M Global Licensing Deal with Percheron Therapeutics
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
Can ProFound Therapeutics and Novartis’ $750M AI-Driven Cardiovascular Pact Redefine Drug Discovery from the Human Proteome?
Key Highlights AI Meets Proteomics: A New Paradigm in Cardiovascular DiscoveryIn a bold step toward AI-enabled medicine, ProFound…
Is Insilico’s AI-Driven UAE University Alliance the Catalyst for a New Generation of Biotech Talent?
Key Highlights Academic Meets AI Innovation in UAEInsilico Medicine, a leader in generative AI for drug discovery, has…
Is Sanofi’s $632M AI Bet on Formation Bio the Next Big Immunology Breakthrough?
French pharma giant doubles down on AI-native R&D with gusacitinib licensing deal targeting new inflammatory indication Key Takeaways…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights from Pharma’s Biggest AI Alliances
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Is Merck’s WINREVAIR Set to Redefine First-Year PAH Treatment? Phase 3 HYPERION Results Show Over 70% Clinical Event Risk Reduction in Newly Diagnosed Patients
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP, Redefine Frontline Standards in Transplant-Eligible Multiple Myeloma?
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2 Diabetes Treatment? Complete Phase 3 Results Show Compelling Efficacy and Safety on Par with Injectable GLP-1 Therapies
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout Moment for AI-Powered TechBio in Oncology and Beyond?
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Is Eli Lilly’s $1.3B Acquisition of Verve the Turning Point for CRISPR-Based Cardiovascular Therapies?
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion marks…
Is HEALWELL AI’s Acquisition of BioPharma Canada’s Biggest AI-Driven CRO Leap Yet—and a Blueprint for Future Clinical Trials?
Key Highlights HEALWELL Targets AI-Driven Scale in CRO with $14.4M BioPharma AcquisitionHEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)…
